Format

Send to

Choose Destination
Nat Rev Drug Discov. 2017 Jan;16(1):1-2. doi: 10.1038/nrd.2016.205. Epub 2016 Nov 4.

Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS.

Author information

1
Department of Neurochemistry and Neuropharmacology, Institut d'Investigacions Biomèdiques de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC), 08036 Barcelona, Spain.
2
CIBERSAM (Centro de Investigació Biomédica en Red de Salud Mental), 28029 Madrid, Spain.
3
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
4
Institute de Recherches SERVIER, 78290 Croissy sur Seine, France.
5
Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
6
UMR_S 894 Inserm, Centre de Psychiatrie et Neurosciences, 75014 Paris, France.
7
Université Pierre et Marie Curie (UPMC), CNRS UMR, 8246, INSERM U1130, 75252 Paris, France.
8
Pfizer Global Research, 610 Main Street, Cambridge, Massachusetts 02139, USA.
9
AbbVie Deutschland GmbH &Co. KG, Knollstrasse, Ludwigshafen 67061, Germany.
10
Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim 68159, Germany.
11
Lundbeck A/S, 2500 Valby, Denmark.
12
Lilly Centre for Cognitive Neuroscience, Eli Lilly &Co. Ltd, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK.
13
CNS Biomarker, Pharmaceuticals Division, F. Hoffmann-La Roche, 4070 Basel, Switzerland.
14
Lilly Research Laboratories, 835 S Delaware Street, Indianapolis, Indiana 46285, USA.

Abstract

Despite the vast amount of research on schizophrenia and depression in the past two decades, there have been few innovative drugs to treat these disorders. Precompetitive research collaborations between companies and academic groups can help tackle this innovation deficit, as illustrated by the achievements of the IMI-NEWMEDS consortium.

PMID:
27811930
DOI:
10.1038/nrd.2016.205
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center